{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:19:43Z","timestamp":1773303583798,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Results from a phase III, randomized, double-blind, active comparator-controlled, parallel-group trial evaluating fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) found that a single-day, triple-antiemetic fosaprepitant regimen resulted in a significantly higher proportion of patients achieving a complete response (CR; no vomiting or rescue medication use) in the delayed phase (25\u2013120\u2009h after chemotherapy initiation), compared with a 3-day control regimen (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, NCT01594749). As the risk for CINV is dependent on chemotherapy regimen and generally guided by tumor type, this post hoc analysis evaluated the efficacy and safety of this regimen by cancer subpopulations (gastrointestinal [GI] or colorectal, lung, breast, and gynecologic cancers).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Subjects with confirmed cancer who were naive to highly and moderately emetogenic chemotherapy (HEC and MEC) and were scheduled to receive intravenous (IV) anthracycline-cyclophosphamide (AC)\u2013based MEC on the first day of chemotherapy were randomly assigned to receive oral ondansetron and oral dexamethasone plus either a single IV dose of fosaprepitant 150\u2009mg (fosaprepitant regimen) or placebo (control regimen). The primary efficacy end point was the proportion of subjects achieving CR in the delayed phase. CR rates in the overall and acute phases (0\u2013120\u2009h and 0\u201324\u2009h after MEC initiation, respectively) were assessed as secondary end points. Safety and tolerability were also assessed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>CR rates in the delayed phase favored the fosaprepitant regimen over the control regimen across the GI\/colorectal, lung, breast, and gynecologic cancer subgroups (range, 6.2\u201322%); similar findings were observed for CR in the overall phase. CR in the acute phase was high for all groups (\u226587%). The fosaprepitant regimen was well tolerated in all cancer subgroups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This post hoc analysis indicated that a single-day fosaprepitant regimen was effective in preventing CINV in patients receiving MEC, regardless of cancer type.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01594749?term=NCT01594749&amp;draw=2&amp;rank=1\">NCT01594749<\/jats:ext-link>, registered May 9, 2012.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07259-5","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T15:03:47Z","timestamp":1601305427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type"],"prefix":"10.1186","volume":"20","author":[{"given":"Cindy","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleem","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Beckford-Brathwaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldimir","family":"Vallejos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annpey","family":"Pong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Noga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"7259_CR1","first-page":"151","volume":"3","author":"VT Chan","year":"2011","unstructured":"Chan VT, Yeo W. Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer (Auckl). 2011;3:151\u201360.","journal-title":"Breast Cancer (Auckl)"},{"key":"7259_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ygyno.2015.12.029","volume":"140","author":"M Mizuno","year":"2016","unstructured":"Mizuno M, Hiura M, Kikkawa F, et al. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV study group of Japan. Gynecol Oncol. 2016;140:559\u201364.","journal-title":"Gynecol Oncol"},{"key":"7259_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/mco.2012.33","volume":"1","author":"A Ishikawa","year":"2013","unstructured":"Ishikawa A, Ohara G, Nakazawa K, et al. Chemotherapy-induced complications in patients with lung cancer: an evaluation by pharmacists. Mol Clin Oncol. 2013;1:65\u20138.","journal-title":"Mol Clin Oncol"},{"key":"7259_CR4","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119\u2013v33.","journal-title":"Ann Oncol"},{"key":"7259_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26:1081\u201390.","journal-title":"Ann Oncol"},{"key":"7259_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Antiemesis. Version 2. 2017 \u2014 March 28, 2017."},{"key":"7259_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191\u20136.","journal-title":"Oncologist"},{"key":"7259_CR8","unstructured":"Oncology Nursing Society. Emetogenic risk of chemotherapy and biotherapy agents. In: Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice, vol. 2. 3rd ed. Pittsburgh: Oncology Nursing Society; 2018."},{"key":"7259_CR9","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240\u201361.","journal-title":"J Clin Oncol"},{"key":"7259_CR10","unstructured":"Merck Sharp & Dohme Corp. EMEND (fosaprepitant) for injection, for intravenous use. Whitehouse Station: Merck Sharp & Dohme Corp; 2018."},{"key":"7259_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27:172\u20138.","journal-title":"Ann Oncol"},{"key":"7259_CR12","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932\u201347.","journal-title":"J Clin Oncol"},{"key":"7259_CR13","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189\u201398.","journal-title":"J Clin Oncol"},{"key":"7259_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist. 2015;20:576\u201383.","journal-title":"Oncologist"},{"key":"7259_CR15","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"7259_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213\u201326.","journal-title":"Stat Med"},{"key":"7259_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"7259_CR18","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28:1260\u20137.","journal-title":"Ann Oncol"},{"key":"7259_CR19","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00520-018-4242-x","volume":"26","author":"C Weinstein","year":"2018","unstructured":"Weinstein C, Jordan K, Green SA, et al. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Support Care Cancer. 2018;26:3773\u201380.","journal-title":"Support Care Cancer"},{"key":"7259_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","volume":"16","author":"BL Rapoport","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079\u201389.","journal-title":"Lancet Oncol"},{"key":"7259_CR21","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.2147\/DDDT.S133943","volume":"11","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL, Aapro M, Chasen MR, et al. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017;11:2621\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"7259_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ctrv.2012.09.002","volume":"39","author":"MS Aapro","year":"2013","unstructured":"Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev. 2013;39:113\u20137.","journal-title":"Cancer Treat Rev"},{"key":"7259_CR23","doi-asserted-by":"publisher","first-page":"84533","DOI":"10.18632\/oncotarget.13023","volume":"7","author":"XH Zhang","year":"2016","unstructured":"Zhang XH, Hao S, Gao B, et al. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic\/advanced breast cancer. Oncotarget. 2016;7:84533\u201343.","journal-title":"Oncotarget"},{"key":"7259_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3332\/ecancer.2018.883","volume":"12","author":"M Casamayor","year":"2018","unstructured":"Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12:883.","journal-title":"Ecancermedicalscience"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07259-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:23:40Z","timestamp":1632525820000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07259-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7259"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07259-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"22 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study. The protocol was approved by institutional review boards or ethics committees at all sites (names listed in Additional\u00a0file\u00a0).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Weinstein is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. Dr. Jordan served as an advisor for Merck Sharp & Dohme Corp., Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med, Pharma Mar, Prime Oncology, OnkoUpdate, <i>Annals of Oncology<\/i>, and UpToDate. Dr. Green is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. Dr. Khanani has nothing to disclose. Dr. Beckford-Brathwaite was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Dr. Vallejos is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. Dr. Pong is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. Dr. Noga is now an employee of Takeda Oncology. Dr. Rapoport served as an advisor for Merck Sharp & Dohme Corp., Tesaro, and Heron Therapeutics, and acted on speakers\u2019 bureaus for Merck Sharp & Dohme Corp., Roche, and Tesaro, and received a research grant from Tesaro.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"918"}}